SciClone Pharmaceuticals (Holdings) Limited announced that the Commercial Launch Conference of DANYELZA (naxitamab) ("DANYELZA") was held on July 1, 2023. The first batch of prescriptions of DANYELza has been issued. With the official commercialization in China, the Company is well prepared to provide this new immunotherapeutic approach to patients with relapsed or refractory high risk neuroblastoma in China.

DANYELZA is approved by the National Medical Products Administration (the "NMPA") in China for the treatment, in combination with granulocyte-macrophage colony-stimulating factor (" GM-CSF"), of pediatric patients of 1 year of age and older and adult patients with relapsed or ref refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. Prior to the approval by the NMPA, benefitting from policy support in China, SciClone Pharmaceuticals pilot launched DANYELZA in Hainan Bo'Ao Lecheng International Medical Tourism Pilot Zone and China (Tianjin) Pilot Free Trade Zone in June 2021 and December 2021, respectively. Since January 2022, SciClone Pharmaceuticals has been selling DANYELZA In Taiwan based on local special import policy.

The Company is also actively seeking to expand the disease indications that may be addressed using DANYELZA. For instance, the Company is preparing for studies aiming to explore the treatment of DANYELZA in other solid tumors with high GD2 expression.